SK hynix Inc. (or "the company", announced today that it will open a customer exhibition booth at Venetian Expo and showcase ...

At ASH 2025, investigators reported early results from the first-in-human phase 1 inMMyCAR study evaluating KLN-1010, an ...

Neoantigens are unique markers that distinguish only cancer cells. By adding B cell reactivity, cancer vaccines can move ...

KAIST Professor Jung Kyoon Choi, Dr. Jeong Yeon Kim, and Dr. Jin Hyeon An >Neoantigens are unique markers that distinguish only cancer ...

The debut of DeepSeek R1 sent ripples through the AI community, not just for its capabilities, but also for the sheer scale of its development. The 671-billion-parameter, open-source language model’s ...

An expert discusses IL-18-armored CAR T cells for adults with relapsed B-cell leukemia, showing complete remissions with manageable side effects. In an onsite interview with CURE at the 2025 ASH ...

– New collaboration builds on Sanofi’s prior acquisition of DR-0201 and further leverages Dren Bio’s proprietary Targeted Myeloid Engager and Phagocytosis Platform to discover first-in-class ...

Japanese semiconductor test equipment manufacturer Advantest has announced the launch of a next-generation memory handler, designed specifically for high-performance memory components used in ...

Researchers at the Keck School of Medicine of University of Southern California (USC) have developed a new type of chimeric antigen receptor (CAR) T cell that elicits a more controlled immune response ...

Safety and efficacy data from a phase 1 multicenter study evaluating rapcabtagene autoleucel, an investigational next-generation CD19-directed CAR-T cell therapy that is manufactured in 48 hours using ...

Two-year follow up from Arm 8 of the EPCORE NHL-2 trial (abstract 64) showed fixed-duration epcoritamab plus rituximab plus dose-attenuated cyclophosphamide, doxorubicin, vincristine, and prednisone ...